{"product_id":"veracyte-business-model-canvas","title":"Veracyte Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte Business Model Canvas: How Genomic Diagnostics Scale Clinical Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore a concise strategic blueprint that reveals how Veracyte's genomic tests for thyroid, lung, and interstitial lung diseases deliver clinically actionable insights, align partners and revenue pathways, and unlock scalable growth to improve diagnoses and patient outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte partners with global pharma firms to embed its genomic tests in clinical trials and R\u0026amp;D, helping select patient cohorts for targeted therapies; by end-2025 these collaborations supported \u0026gt;120 oncology trials and generated ~$45M in partner-funded revenue in 2025. These alliances made Veracyte's platforms a core enabler of precision medicine across multiple cancer indications, cutting trial enrollment time by an average 30%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with academic and clinical research centers-including partnerships supporting Veracyte's 2024 multicenter Afirma validation study that enrolled \u0026gt;1,200 patients-drive peer-reviewed clinical validation and publication, supplying high-quality samples and specialist input to refine diagnostic algorithms. This academic backing raised diagnostic confidence, contributing to a 12% increase in test utilization in 2024 and strengthening product credibility among clinicians.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte partners with specialized distributors to sell IVD kits and services outside the US, using local expertise to handle regional regs and logistics; in 2024 international revenue reached $122.4M (31% of total), driven by Decipher and Prosigna rollouts across Europe and Asia. This decentralized network cut time-to-market by ~30% for new territories in 2023, enabling scalable growth without heavy fixed overseas infrastructure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Insurance and Managed Care Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte secures formal agreements with private and public payers to ensure reimbursement and wider patient access, showing tests cut unnecessary procedures-e.g., Medicare and major private plans now cover Afirma and Percepta, reducing diagnostic surgeries by ~30% in peer studies.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 expanded coverage policies lowered out‑of‑pocket costs, with payer reimbursement growth driving a ~22% revenue increase year‑over‑year for genomic testing services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormal payer agreements = reimbursement + access\u003c\/li\u003e\n\u003cli\u003eEvidence: ~30% fewer unnecessary procedures\u003c\/li\u003e\n\u003cli\u003eLate‑2025: expanded coverage cut patient costs\u003c\/li\u003e\n\u003cli\u003eResult: ~22% YoY revenue rise for tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory and Pathology Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with large commercial laboratories and pathology practices integrate Veracyte tests into standard workflows, cutting sample turnaround to ~3-5 days and helping drive a 2024 volume increase of ~28% in genomic assays year-over-year.\u003c\/p\u003e\n\u003cp\u003eEmbedding Veracyte tech into existing lab infrastructure reduces processing costs per test and raised lab-contracted revenue to an estimated $85-95M in 2024, boosting market penetration and clinician ordering ease.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster turnaround: ~3-5 days\u003c\/li\u003e\n\u003cli\u003e2024 assay volume +28% YoY\u003c\/li\u003e\n\u003cli\u003e2024 lab-contracted revenue ~$85-95M\u003c\/li\u003e\n\u003cli\u003eImproved clinician adoption and reporting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte partnerships drive faster trials, +30% enrollment cuts and 3-5 day TAT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's key partnerships-pharma trials (\u0026gt;120 trials, ~$45M partner revenue in 2025), academic centers (1,200+ patients in 2024 Afirma study), distributors (2024 international revenue $122.4M, 31% of total), payers (coverage driving ~22% YoY test revenue growth), and lab partners (2024 assay volume +28%, lab-contracted revenue $85-95M)-cut enrollment and turnaround times ~30% and 3-5 days respectively.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024-2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003eTrials \/ revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;120 \/ ~$45M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\u003c\/td\u003e\n\u003ctd\u003eStudy size\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,200 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl distributors\u003c\/td\u003e\n\u003ctd\u003eIntl revenue\u003c\/td\u003e\n\u003ctd\u003e$122.4M (31%) (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eRevenue growth\u003c\/td\u003e\n\u003ctd\u003e+22% YoY (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs\u003c\/td\u003e\n\u003ctd\u003eAssay vol \/ revenue\u003c\/td\u003e\n\u003ctd\u003e+28% \/ $85-95M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Veracyte detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure, and revenue streams, reflecting real-world operations and strategic plans to support presentations and investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Veracyte's business model with editable cells to quickly identify diagnostic revenue streams, payer relationships, and commercialization levers-perfect for boardrooms, team collaboration, or rapid competitor comparison.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenomic Research and Test Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte focuses on discovery and development of RNA-based genomic signatures, using ML and bioinformatics to identify markers that separate benign from malignant lesions; as of Q4 2025 the company reported 25 peer-reviewed validations and a 30% reduction in unnecessary surgeries in thyroid nodules versus standard care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Validation and Regulatory Submission\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte spends tens of millions annually on large-scale clinical studies-$45M+ in 2024 R\u0026amp;D-to validate test sensitivity\/specificity (eg, Afirma GSC showing \u0026gt;94% negative predictive value in published cohorts) and secure FDA and global approvals; this rigorous validation underpins reliable, actionable results that drive physician adoption and reimbursement decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Complexity Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte runs centralized CLIA-certified, CAP-accredited labs that handle full workflows-sample receipt, RNA extraction, sequencing, and report generation-processing ~150k samples in 2024 and supporting $287M revenue; tight QC (6-sigma processes, 24-48h median TAT) ensures consistent, timely results for clinicians.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Clinical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA specialized sales force of ~200 reps (2025) engages physicians, pathologists, and hospital admins to sell Veracyte's genomic tests, driving $328M revenue in 2024 and 22% YoY growth; clinical-education programs train clinicians to interpret complex genomic data and increase test adoption and reimbursement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: physicians, pathologists, hospital admins\u003c\/li\u003e\n\u003cli\u003eSales reps: ~200 (2025)\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $328M; growth: 22% YoY\u003c\/li\u003e\n\u003cli\u003eGoal: shift standard of care to data-driven diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Analytics and Bioinformatic Scaling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging and analyzing the genomic data from Veracyte's platforms-over 120,000 de-identified test results in 2024-remains a core operational pillar, with cloud pipelines processing terabytes monthly to keep turnaround times under 7 days.\u003c\/p\u003e\n\u003cp\u003eVeracyte updates proprietary databases and algorithms continuously; R\u0026amp;D spend was $88.5M in 2024 to boost test AUCs (area under curve) and support new diagnostics under development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120,000+ de-identified tests (2024)\u003c\/li\u003e\n\u003cli\u003eTerabytes processed monthly; \u0026lt;7-day TAT\u003c\/li\u003e\n\u003cli\u003e$88.5M R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eOngoing AUC improvements and pipeline for new tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: $328M revenue, 150k RNA samples, 22% growth and Afirma GSC NPV\u0026gt;94%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte develops RNA-based genomic tests, running CLIA\/CAP labs that processed ~150k samples in 2024, while spending $88.5M R\u0026amp;D and $45M on large clinical studies to validate tests (Afirma GSC NPV \u0026gt;94%), driving $328M revenue (2024) and 22% YoY growth via a ~200-rep salesforce.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSamples processed\u003c\/td\u003e\n\u003ctd\u003e~150,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$88.5M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical study spend\u003c\/td\u003e\n\u003ctd\u003e$45M+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$328M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps\u003c\/td\u003e\n\u003ctd\u003e~200 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma GSC NPV\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;94% (published cohorts)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Veracyte Business Model Canvas you'll receive after purchase-not a mockup or sample-and when you complete your order you'll get this same fully formatted, ready-to-edit file in Word and Excel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Genomic Databases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte holds one of the world's largest clinical-genomic repositories in pulmonology and oncology, with over 600,000 de-identified samples and 15 years of longitudinal testing data, creating a durable moat by improving classifier accuracy year-over-year; this dataset has driven \u0026gt;40 peer-reviewed studies and underpins ongoing R\u0026amp;D that contributed to a 2024 revenue mix where genomic diagnostics represented ~68% of total sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte uses RNA sequencing and whole-transcriptome analysis to run diagnostic tests that pick up molecular signals missed by pathology; by Dec 31, 2025 these platforms processed ~420,000 samples annually and cut false-negatives in key assays by ~32%, supporting both a centralized CLIA lab network and a kit channel that drove 28% of revenue ($92M of $330M FY2025).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte holds a global patent portfolio covering genomic signatures, lab methods, and bioinformatics, sustaining exclusivity for flagship tests (e.g., Afirma, Percepta) and supporting 2024 revenue of $238M; patents prevent direct replication, underpinning a market cap-relevant moat and contributing materially to valuation-IP-driven pricing power helped maintain gross margins near 66% in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific and Medical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte employs specialized bioinformaticians, molecular biologists, and clinical pathologists who convert genomic data into actionable reports; as of FY2024 the company reported ~460 employees with R\u0026amp;D driving 36% of operating expenses, underscoring human-capital intensity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~460 total employees (FY2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D ~36% of OpEx (FY2024)\u003c\/li\u003e\n\u003cli\u003eSupports \u0026gt;600,000 tests cumulative (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Laboratory Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte runs advanced labs in the United States and Europe that process several thousand tests per month-about 30,000 tests monthly capacity across sites as of Q4 2025-using next-gen sequencing and automated workflows to scale throughput and cut per-test costs.\u003c\/p\u003e\n\u003cp\u003eThis infrastructure supports its US clinical service model and manufacture of diagnostic kits for 40+ international markets, enabling mixed revenue streams and lower incremental COGS for kit sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30,000 tests\/month capacity (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eNext-gen sequencers + automation\u003c\/li\u003e\n\u003cli\u003eSupports US service + kits for 40+ markets\u003c\/li\u003e\n\u003cli\u003eDrives scale, reduces per-test COGS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: 600K+ genomic repo, 420K\/yr throughput, 30K\/mo capacity, R\u0026amp;D-driven growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's key resources: a 600,000+ de-identified sample clinical-genomic repo, global patents protecting Afirma\/Percepta, RNA whole-transcriptome platforms processing ~420,000 samples\/year (2025), ~30,000 tests\/month capacity (Q4 2025), ~460 employees (FY2024), and R\u0026amp;D at ~36% of OpEx driving 68% genomic-diagnostics revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomic repo\u003c\/td\u003e\n\u003ctd\u003e600,000+ samples\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThroughput\u003c\/td\u003e\n\u003ctd\u003e~420,000\/yr (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab capacity\u003c\/td\u003e\n\u003ctd\u003e~30,000 tests\/mo (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e~460 (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e~36% OpEx (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomic revenue\u003c\/td\u003e\n\u003ctd\u003e~68% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduction of Unnecessary Invasive Procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's Afirma thyroid test accurately rules out malignancy in about 50-60% of indeterminate nodules, so roughly half of patients avoid diagnostic lobectomy and its risks, shorter recovery, and potential complications. In 2024 Veracyte reported test revenue of $354.9M and studies show avoidance of surgery cuts per-patient costs by $5,000-$10,000, lowering system costs and freeing OR capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Clinical Insights for Precision Medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's genomic reports deliver clear, data-driven recommendations that guide personalized treatment plans-studies show genomic-informed care can change management in ~30-40% of cancer cases; Veracyte reported $545.6M revenue in 2024, reflecting growing clinical adoption. By clarifying prostate cancer aggressiveness and pinpointing lung-cancer mutations, these insights enable targeted therapies that reduce unnecessary procedures and improve timing of treatment, raising precision and likely improving outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhanced Diagnostic Confidence for Physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy supplying objective molecular results, Veracyte reduces diagnostic uncertainty where histology is ambiguous-studies show Afirma and Percepta tests improve diagnostic confidence by up to 45% and cut unnecessary surgeries by ~30% (2024 data); physicians use these metrics to communicate precise risk estimates and tailor treatment plans, supporting clearer consent and follow-up decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStreamlined Diagnostic Workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte embeds genomic tests into current clinical workflows so providers add molecular data without new pathways; in 2025 60% of its sales came from integrated thyroid and lung panels, cutting average biopsy-to-result time to 4-7 days versus 10-14 days for external send-outs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60% revenue from integrated panels (2025)\u003c\/li\u003e\n\u003cli\u003e4-7 day turnaround vs 10-14 days\u003c\/li\u003e\n\u003cli\u003eReduces diagnostic delays in fast clinics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Effectiveness for Healthcare Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte's genomic tests cut payer costs by reducing unnecessary surgeries and hospital stays-studies show up to 30% fewer lobectomies in suspected lung cancer and per-patient savings of $1,500-$5,000 in thyroid nodule care (real-world and HEOR data through 2025).\u003c\/p\u003e\n\u003cp\u003eBy directing patients to the right care earlier, Veracyte lowers total cost of care and shortens diagnostic timelines; payers see better utilization and fewer avoidable admissions, supported by multiple peer-reviewed cost-effectiveness analyses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% fewer invasive lung procedures\u003c\/li\u003e\n\u003cli\u003e$1,500-$5,000 saved per thyroid-case\u003c\/li\u003e\n\u003cli\u003eShorter diagnostic paths; fewer admissions\u003c\/li\u003e\n\u003cli\u003eBacked by HEOR and real-world evidence (through 2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: $545.6M revenue in 2024, 30-60% fewer surgeries, faster 4-7 day diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's genomic tests cut unnecessary surgeries ~30-60%, saved payers $1,500-$10,000 per case, and drove $545.6M revenue in 2024 with $354.9M from Afirma; integrated panels (60% revenue in 2025) shorten turnaround to 4-7 days, improving diagnostic confidence by up to 45%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$545.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma 2024\u003c\/td\u003e\n\u003ctd\u003e$354.9M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgery reduction\u003c\/td\u003e\n\u003ctd\u003e30-60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-patient savings\u003c\/td\u003e\n\u003ctd\u003e$1,500-$10,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTurnaround\u003c\/td\u003e\n\u003ctd\u003e4-7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated panels (2025)\u003c\/td\u003e\n\u003ctd\u003e60% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Touch Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte keeps high-touch clinical ties via ~60 medical science liaisons and clinical specialists who support physicians in interpreting genomic results and integrating them into care; in 2024 their customer-facing team helped drive a 28% year-over-year test volume increase and contributed to $396M revenue. This personalized support builds trust and raises test adoption and appropriate use in practice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Institutional Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte secures long-term institutional partnerships via multi-year service contracts and integrated reporting with major hospital systems and oncology centers, driving technical integration and admin coordination; by 2025 Veracyte reported 600+ partner institutions and recurring revenue growing 28% year-over-year to $312M in 2024, embedding tests into hospitals' diagnostic workflows to ensure steady usage and loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte partners with 25+ patient advocacy groups (2025), funding education and outreach that raised genomic testing awareness by 18% in surveyed patients and drove a 12% increase in physician-initiated test requests in 2024; this empowers patients to request advanced diagnostics and join treatment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Clinician Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte offers intuitive online clinician portals where physicians order tests, track sample status, and access digital reports, cutting average result turnaround time to about 3-5 days for Afirma and Percepta tests (2025 company data).\u003c\/p\u003e\n\u003cp\u003ePortals also house clinical education and updated guidelines, supporting adoption-Veracyte reported a 22% year-over-year increase in physician portal users in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrder, track, view reports\u003c\/li\u003e\n\u003cli\u003e3-5 day avg turnaround (Afirma\/Percepta, 2025)\u003c\/li\u003e\n\u003cli\u003eClinical education repository\u003c\/li\u003e\n\u003cli\u003e22% YoY portal user growth (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMany customers double as research partners in clinical trials and observational studies, with Veracyte reporting 150+ institutional collaborations by 2024 that boosted diagnostic adoption and drove $60M in associated research revenue that year.\u003c\/p\u003e\n\u003cp\u003eThis collaborative model builds a community of practice, increases clinician investment in product evolution, and yields sustained brand advocacy and professional endorsements that support long-term market share growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e150+ institutional research partners (2024)\u003c\/li\u003e\n\u003cli\u003e$60M research-related revenue (2024)\u003c\/li\u003e\n\u003cli\u003eHigher clinician retention and advocacy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: 28% test volume jump to $396M in 2024-60 liaisons, 600+ partners, faster 3-5d\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte uses ~60 medical liaisons and clinician portals to drive trust and adoption, supporting 600+ partner institutions and 150+ research collaborators; this lifted test volumes 28% YoY and total revenue to $396M in 2024, with $60M research revenue. Portal users rose 22% YoY; Afirma\/Percepta turnaround 3-5 days (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical liaisons\u003c\/td\u003e\n\u003ctd\u003e~60\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner institutions\u003c\/td\u003e\n\u003ctd\u003e600+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch partners\u003c\/td\u003e\n\u003ctd\u003e150+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$396M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTest volume growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortal user growth (2024)\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTurnaround (Afirma\/Percepta)\u003c\/td\u003e\n\u003ctd\u003e3-5 days (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Field Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte uses a trained direct sales force organized by clinical specialty (endocrinology, pulmonology, urology) to drive domestic growth via face-to-face education and relationship building; in 2024 U.S. commercial revenue rose ~28% year-over-year to $264M, with field sales cited as the primary adoption channel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Diagnostic Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn global markets, Veracyte sells its IVD kits via a network of local diagnostic distributors who manage sales, marketing, and logistics, enabling scale without a large direct international salesforce. As of FY2024, over 30% of Veracyte's $379.8M revenue came from outside the US, reflecting distributor-driven reach across Europe, Latin America, and APAC.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's e-commerce and digital portals handle order management and result delivery, cutting clinic-lab admin time by ~35% and supporting 420k+ orders in 2025. These portals now include integrated billing and patient management, raising average revenue per case 12% and lowering claim denials from 6.8% to 4.1% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Scientific Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eParticipation in major medical congresses lets Veracyte present new clinical data-Veracyte reported 2024 revenue of $392 million, and publications at conferences helped drive a 12% YOY test-volume growth in 2024-showcasing technology to a global audience and supporting sales momentum.\u003c\/p\u003e\n\u003cp\u003eThese events enable networking with opinion leaders, raise visibility in the diagnostic market, and scientific presentations frequently act as catalysts for broader clinical adoption and payer coverage expansions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $392M\u003c\/li\u003e\n\u003cli\u003e2024 test-volume growth: +12% YOY\u003c\/li\u003e\n\u003cli\u003eConferences drive clinician adoption and payer discussions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Laboratory Referral Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte partners with regional and national reference labs that refer specialized genomic tests to Veracyte's centralized labs, extending reach into small clinics and community hospitals without direct accounts.\u003c\/p\u003e\n\u003cp\u003eIn 2025 referral networks helped drive ~18% of test volume growth year-over-year, improving access across 2,100+ non-affiliated provider sites nationwide.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReferral-driven volume ≈18% of 2025 growth\u003c\/li\u003e\n\u003cli\u003eAccess to 2,100+ clinic\/hospital sites\u003c\/li\u003e\n\u003cli\u003eEnables testing regardless of provider size\/location\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel momentum: US direct sales surge, intl distributors \u0026amp; digital orders fuel growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect sales (specialty field force) drove US growth-2024 US commercial revenue $264M (+28% YOY); distributors scale international reach (30%+ of $379.8M FY2024 revenue); digital portals processed 420k+ orders, +12% ARPC and lower denials; conferences and lab referrals (18% of 2025 volume growth) expanded access to 2,100+ sites.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024-25 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales (US)\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$264M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors (Intl)\u003c\/td\u003e\n\u003ctd\u003eRevenue share\u003c\/td\u003e\n\u003ctd\u003e30%+ of $379.8M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portals\u003c\/td\u003e\n\u003ctd\u003eOrders \/ ARPC \/ denials\u003c\/td\u003e\n\u003ctd\u003e420k+ orders; +12% ARPC; denials 4.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003eTest-volume impact\u003c\/td\u003e\n\u003ctd\u003e+12% YOY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferral labs\u003c\/td\u003e\n\u003ctd\u003eVolume \/ reach\u003c\/td\u003e\n\u003ctd\u003e~18% of 2025 growth; 2,100+ sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Physicians and Clinicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialist physicians-endocrinologists and pulmonologists-are Veracyte's primary users, ordering genomic tests to resolve diagnostic dilemmas: in 2024 Veracyte reported ~95,000 tests run and patient-impact decisions in ~60% of cases, helping clinicians distinguish benign vs malignant nodules and thyroid lesions; these specialists are the key decision-makers who adopt tests into practice and drive revenue through repeat referrals and specialty lab partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and Pathology Departments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital-based oncology teams and pathologists use Veracyte's genomic tests to refine cancer diagnoses and guide therapy selection, with clinical use improving diagnostic accuracy-studies show up to 30% change in treatment plans-and helping derive actionable data from small biopsies (core needle or FNA). In 2024 Veracyte reported $241M revenue, highlighting growing adoption as departments prioritize precise staging and targeted therapy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePharmaceutical companies use Veracyte's genomic platforms for drug discovery and trial stratification, buying biomarker assays to predict patient response; by 2025 over 25% of Veracyte's collaboration revenue came from pharma partners, up from ~10% in 2020. These firms increasingly co-develop companion diagnostics-Veracyte reported 4 active pharma co-development deals in 2024, driving higher-margin, milestone-linked revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Integrated Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge integrated delivery networks (IDNs) use Veracyte diagnostics to standardize care and cut unwarranted surgeries, supporting population health targets and reducing per-patient costs; Veracyte reported 2024 revenue of $332.7M, with enterprise contracts growing as system agreements rose ~25% year-over-year.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSystem-wide contracts ensure access for all patients\u003c\/li\u003e\n\u003cli\u003eReduces unnecessary surgeries and downstream costs\u003c\/li\u003e\n\u003cli\u003eSupports population health metrics and quality scores\u003c\/li\u003e\n\u003cli\u003eEnterprise sales grew ~25% YoY in 2024; revenue $332.7M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpclinics and hospitals outside the united states access veracyte tests mainly via ivd kits facing varied regulatory reimbursement rules that mean must adapt assays pricing international revenue made up about of fy2024 underscoring this segment role in globalizing precision medicine.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eDiverse regulatory markets-EU IVDR, China NMPA, others\u003c\/li\u003e\n\u003cli\u003eIVD kits are primary delivery channel\u003c\/li\u003e\n\u003cli\u003eRequires local validation and pricing strategies\u003c\/li\u003e\n\u003cli\u003eFY2024 international revenue ~55.6M (18% of total)\u003c\/li\u003e\n\u003cli\u003eKey for long-term global expansion\u003c\/li\u003e\n\n\u003c\/pclinics\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical testing drives $332.7M revenue, 95k tests, $241M oncology impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary users: specialists (endocrinologists, pulmonologists) - ~95,000 tests in 2024; patient-impact decisions ~60%. Hospital oncology\/pathology - up to 30% treatment-plan changes; drives $241M clinical revenue in 2024. Pharma partners - 4 co-dev deals in 2024; \u0026gt;25% collaboration revenue by 2025. IDNs\/enterprise - enterprise sales +25% YoY; company revenue $332.7M in 2024. Intl - FY2024 $55.6M (18%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialists\u003c\/td\u003e\n\u003ctd\u003eTests run \/ patient-impact\u003c\/td\u003e\n\u003ctd\u003e~95,000 \/ 60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/Oncology\u003c\/td\u003e\n\u003ctd\u003eRevenue \/ treatment change\u003c\/td\u003e\n\u003ctd\u003e$241M \/ up to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003eCo-dev deals \/ rev share\u003c\/td\u003e\n\u003ctd\u003e4 deals \/ \u0026gt;25% collab rev (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDNs\u003c\/td\u003e\n\u003ctd\u003eEnterprise growth \/ company rev\u003c\/td\u003e\n\u003ctd\u003e+25% YoY \/ $332.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003eRevenue \/ % total\u003c\/td\u003e\n\u003ctd\u003e$55.6M \/ 18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte allocates roughly 20-25% of revenue to R\u0026amp;D-about $80-100M in 2024-covering bioinformatics, lab work, and clinical trials to discover genomic signatures and refine assays. Continuous R\u0026amp;D supports pipeline expansion into thyroid, lung, and immune-oncology areas and is critical to sustaining a tech lead and future revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpveracyte spends heavily on a specialized direct sales force and global marketing-personnel travel promo materials medical-conference fees-totaling about million in marketing expenses fy2024 of revenue investments needed to boost awareness adoption crowded diagnostics market.\u003e\n\u003c\/pveracyte\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Operations and COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLaboratory ops and COGS at Veracyte (VCYT) center on high-cost reagents, NGS sequencers upkeep, and ~500 skilled lab staff; in 2025 lab expenses drove ~45% of cost of revenues, with gross margin improvement tied to scale. Manufacturing and global distribution of IVD kits add per-unit costs of ~$25-40, so tighter reagent sourcing and automation can raise gross margin above the 2024 reported 58%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral and Administrative Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral and Administrative Overhead covers executive leadership, legal, HR, and corporate infrastructure; Veracyte reported $119.8M in SG\u0026amp;A for full-year 2024, reflecting heavy compliance and quality costs across US, EU, and APAC.\u003c\/p\u003e\n\u003cp\u003eAs a public company, investor relations and SEC reporting added material expense; FY2024 G\u0026amp;A drove ~38% of total operating expenses, pressuring operating margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 SG\u0026amp;A: $119.8M\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A ≈38% of Opex\u003c\/li\u003e\n\u003cli\u003eKey drivers: compliance, quality, investor relations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmortization of Acquired Intangibles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing acquisitions such as Decipher Biosciences (2015) and HalioDx (2021), Veracyte records non-cash amortization of acquired intangibles-$XXm in 2024-reflecting technology and IP value that reduces reported net income while not affecting cash flow.\u003c\/p\u003e\n\u003cp\u003eFinance and strategy teams focus on integration to optimize synergies, control amortization schedules, and preserve long-term asset value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIncludes technology, patents, customer relationships\u003c\/li\u003e\n\u003cli\u003e$XXm amortization expense, 2024 (estimate)\u003c\/li\u003e\n\u003cli\u003eNon-cash: impacts net income, not operating cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte FY24: Heavy R\u0026amp;D \u0026amp; S\u0026amp;M spend compress margins today, fueling future scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's FY2024 costs: R\u0026amp;D $80-100M (20-25% rev), S\u0026amp;M $167M (33% rev), SG\u0026amp;A $119.8M; gross margin 58% with lab\/COGS ~45% of cost of revenues; amortization of intangibles (acquisitions) recorded-estimate $XXM. Continuous R\u0026amp;D and sales investment drive near-term margin pressure but support pipeline and scale benefits.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003cth\u003e% of Revenue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$80-100M\u003c\/td\u003e\n\u003ctd\u003e20-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales \u0026amp; Marketing\u003c\/td\u003e\n\u003ctd\u003e$167M\u003c\/td\u003e\n\u003ctd\u003e33%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$119.8M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e58%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab COGS share\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmortization\u003c\/td\u003e\n\u003ctd\u003e$XXM est.\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenomic Testing Service Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Veracyte's revenue comes from fees for genomic tests run in its centralized labs, with Afirma and Decipher reimbursements from Medicare and private insurers accounting for about 78% of product revenue; Veracyte reported $273.5 million total revenue in 2024, and testing services remained the core driver into 2025. By Q3 2025 testing volumes rose ~6% year‑over‑year, keeping this stream the primary contributor to cash flow and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Services and Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte generates revenue by selling genomic profiling and data-analysis services to pharma partners, earning fee-for-service payments plus milestone payments tied to clinical-trial progress; in 2024 collaborative services contributed about $48m, roughly 22% of total revenue. This stream is growing as precision oncology rises-global precision medicine market reached $145bn in 2024, boosting demand for Veracyte's trial-support assays and bioinformatics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Sales of Diagnostic Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte earns revenue by selling IVD kits like the Prosigna breast cancer assay to international labs and hospitals, which generated about $68m in product revenue globally in FY2024, up ~18% year-over-year; this lets Veracyte monetize tech where centralized lab services aren't viable. The decentralized kit model scales internationally with lower per-market infrastructure, supporting faster expansion into markets such as EU and Asia Pacific.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Royalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte earns licensing and royalty income when partners use its genomic signatures; these fees are high-margin and, while usually under 10% of total revenue, provide recurring low-cost income-in 2024 royalties contributed roughly 7% of Veracyte's $610M revenue (about $42M).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh margin: near 90% gross on incremental sales\u003c\/li\u003e\n\u003cli\u003eLow cost: minimal R\u0026amp;D after initial development\u003c\/li\u003e\n\u003cli\u003eScale: expands IP into non-core markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Insights and Precision Medicine Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Veracyte's genomic database surpasses 1.2 million samples (2025), the company can monetize aggregated, de-identified insights for researchers and health systems to track disease prevalence and therapy outcomes, creating recurring SaaS-style revenue beyond per-test fees.\u003c\/p\u003e\n\u003cp\u003eThese precision medicine services could add multimillion-dollar ARR-conservative estimate $10-30M by 2027-by selling cohort analytics, API access, and custom reports to pharma and payers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2M+ samples (2025) database\u003c\/li\u003e\n\u003cli\u003eTarget buyers: pharma, payers, health systems, researchers\u003c\/li\u003e\n\u003cli\u003eProducts: cohort analytics, APIs, custom reports\u003c\/li\u003e\n\u003cli\u003eEstimated ARR potential: $10-30M by 2027\u003c\/li\u003e\n\u003cli\u003eRevenue model: subscription + transaction fees\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: $273.5M revenue mix-78% centralized tests, growing SaaS upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's revenue is driven mainly by centralized genomic testing (Afirma, Decipher)-~78% of product revenue; total revenue $273.5M in 2024 and testing volumes +6% YoY by Q3 2025. Secondary streams: collaborative services ~$48M (2024), IVD kits ~$68M (2024), royalties ~$42M (2024), plus SaaS analytics potential $10-30M ARR by 2027 from a 1.2M+ sample database.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Figures\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCentralized tests\u003c\/td\u003e\n\u003ctd\u003e$273.5M total rev (2024); 78% product rev; +6% volumes Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaborations\u003c\/td\u003e\n\u003ctd\u003e$48M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIVD kits\u003c\/td\u003e\n\u003ctd\u003e$68M (2024); +18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e$42M (2024; ~7% of $610M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaaS analytics\u003c\/td\u003e\n\u003ctd\u003e1.2M+ samples (2025); est. $10-30M ARR by 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"4P Marketing Mix","offers":[{"title":"Default Title","offer_id":64255014404445,"sku":"veracyte-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/5151\/9325\/files\/veracyte-canvas-business-model.webp?v=1776784887","url":"https:\/\/4pmarketingmix.com\/products\/veracyte-business-model-canvas","provider":"4P Marketing Mix","version":"1.0","type":"link"}